Drugs / SKG0201
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07554924 | May 2026 → May 2029 expected | spinal muscular atrophy, type 1 | Lanyue Biotech (Hangzhou) Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06191354 | Jun 2023 → Dec 2025 overdue | spinal muscular atrophy, type 1 | Kun Sun | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SKG0201 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07554924 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “SKG0201 is a recombinant adeno-associated virus (rAAV) vector-based in vivo gene therapeutic product.” NCT06191354 ↗ |